Table 1.
Patients' and tumours' characteristics stratified by cases (CH) and extended hepatectomy (EH) groups
| CH group (n = 63) | Right EH group (n = 63) | P-valuea | Combined EH group (N = 63) | P-valueb | |
|---|---|---|---|---|---|
| Demographics | |||||
| Age at surgery, years | 61 (36–86) | 60 (35–81) | 0.9 | 61 (31–81) | 0.7 |
| Male | 44 (70%) | 39 (62%) | 0.4 | 40 (63%) | 0.5 |
| Body mass index, kg/mb | |||||
| <25 | 15 (24%) | 15 (24%) | 1.0 | 15 (24%) | 1.0 |
| 25–29 | 29 (46%) | 29 (46%) | 29 (46%) | ||
| ≥30 | 19 (30%) | 19 (30%) | 19 (30%) | ||
| Tumour characteristics | |||||
| Indication for surgery disease | |||||
| Hepatocellular cancer | 5 (8%) | 5 (8%) | 1.0 | 5 (8%) | 1.0 |
| Metastases – Colorectal | 44 (70%) | 44 (70%) | 44 (70%) | ||
| Metastases – Others | 14 (22%) | 14 (22%) | 14 (22%) | ||
| Largest tumour size, cm | 3.6 (1–21) | 4.1 (2–14) | <0.01 | 4.1 (1–14) | <0.01 |
| Pre-operative investigations | |||||
| Platelets, ×109/l | 214 (95–453) | 207 (112–467) | 0.3 | 210 (112–467) | 0.09 |
| Creatinine, mg/dl | 1.0 (0.6–1.6) | 1.0 (0.6–1.7) | 0.8 | 1.0 (0.6–1.90) | 0.8 |
| International Normalized Ratio | 1.1 (0.9–1.7) | 1.1 (0.9–1.7) | 0.3 | 1.1 (0.88–1.67) | 0.3 |
| Bilirubin, mg/dl | 0.6 (0.3–1.3) | 0.7 (0.2–10.1) | 0.3 | 0.6 (0.2–10.1) | 0.4 |
| Carcinoembryonic antigen, ng/ml [CLM patients only (n = 44)] | 13.7 (1.4–792) | 12.3 (1.1–476) | 0.9 | 20.6 (1.1–475.6) | 0.9 |
| Pre-operative portal vein embolization | 0 | 12 (19%) | <0.001 | 10 (16%) | <0.01 |
CLM, colorectal liver metastasis; Continuous variables are expressed as median (range); categorical variables are expressed as n (%).
a
Comparison of the CH and right EH groups.
b
Comparison of the CH and combined EH groups.
Bold values denote P-values < 0.05.